ERBB2 and neoplasm: Sixty-nine (69%) patients had hormone receptor-positive/HER2+ (HR+/HER2+) disease on primary site tumor, and the remaining 31 (31%) patients had HR-negative/HER2+ (HR−/HER2+) BC.